# A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer

> **NCT04588298** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 135 (actual)

## Conditions studied

- HER2-negative Breast Cancer

## Interventions

- **DRUG:** AZD9833

## Key facts

- **NCT ID:** NCT04588298
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-02
- **Primary completion:** 2023-06-19
- **Final completion:** 2023-06-19
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2025-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04588298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04588298, "A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04588298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*